Investors Press Releases Year All2024202320222021 Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results Nov 14, 2024 Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings Oct 15, 2024 Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications Sep 17, 2024 Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research Aug 14, 2024 Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress Aug 06, 2024 Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors Jun 24, 2024 Omega Therapeutics To Participate In Two Upcoming Investor Conferences May 30, 2024 Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer May 29, 2024 Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers May 08, 2024 Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress May 06, 2024
Year All2024202320222021 Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results Nov 14, 2024 Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings Oct 15, 2024 Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications Sep 17, 2024 Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research Aug 14, 2024 Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress Aug 06, 2024 Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors Jun 24, 2024 Omega Therapeutics To Participate In Two Upcoming Investor Conferences May 30, 2024 Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer May 29, 2024 Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers May 08, 2024 Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress May 06, 2024
